{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:33:55Z","timestamp":1786988035223,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005410","name":"American-Italian Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejca.2024.115097","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T03:05:49Z","timestamp":1730257549000},"page":"115097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study"],"prefix":"10.1016","volume":"213","author":[{"given":"Carmine","family":"Valenza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Zagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Antonarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Boscolo Bielo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Nicol\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana Mourato","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Guidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Reduzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Spotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Adamoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cort\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pistilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Layman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cristofanilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Munzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Criscitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Lynce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy A.","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.115097_bib1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3322\/caac.20082","article-title":"Inflammatory breast cancer: the disease, the biology, the treatment","volume":"60","author":"Robertson","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2024.115097_bib2","doi-asserted-by":"crossref","first-page":"e568","DOI":"10.1016\/S1470-2045(15)00146-1","article-title":"Inflammatory breast cancer: unique biological and therapeutic considerations","volume":"16","author":"Woodward","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.115097_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100220","article-title":"Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)","volume":"6","author":"Dano","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2024.115097_bib4","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.7150\/jca.23969","article-title":"International consensus on the clinical management of inflammatory breast cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference","volume":"9","author":"Ueno","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.ejca.2024.115097_bib5","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2024.115097_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115097_bib7","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.115097_bib8","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115097_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102598","article-title":"The immunogram of inflammatory breast cancer","volume":"119","author":"Valenza","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2024.115097_bib10","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1158\/1535-7163.MCT-15-0353","article-title":"Genomic and immunological tumor profiling identifies targetable pathways and extensive CD8+\/PDL1+ immune infiltration in inflammatory breast cancer tumors","volume":"15","author":"Hamm","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2024.115097_bib11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13058-019-1108-1","article-title":"Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression","volume":"21","author":"Van Berckelaer","year":"2019","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2024.115097_bib12","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.3390\/cancers13184656","article-title":"The evolution and prognostic role of tumour-infiltrating lymphocytes and peripheral blood-based biomarkers in inflammatory breast cancer patients treated with neoadjuvant chemotherapy","volume":"13","author":"Van Berckelaer","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2024.115097_bib13","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1929724","article-title":"Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors","volume":"10","author":"Bertucci","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejca.2024.115097_bib14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/CCO.0000000000000967","article-title":"Immunotherapy for inflammatory breast cancer: current evidences and future perspectives","volume":"35","author":"Valenza","year":"2023","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ejca.2024.115097_bib15","series-title":"Group Sequential Methods with Applications to Clinical Trials","author":"Jennison","year":"1999"},{"key":"10.1016\/j.ejca.2024.115097_bib16","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.annonc.2024.04.001","article-title":"IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer","volume":"35","author":"Dent","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.115097_bib17","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115097_bib18","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.115097_bib19","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10549-018-4715-0","article-title":"Factors associated with improved outcomes for metastatic inflammatory breast cancer patients","volume":"169","author":"Weiss","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2024.115097_bib20","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1245\/s10434-018-6494-6","article-title":"Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01","volume":"25","author":"Soran","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2024.115097_bib21","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S1470-2045(15)00135-7","article-title":"Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial","volume":"16","author":"Badwe","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.115097_bib22","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s10549-012-2133-2","article-title":"Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the surveillance, epidemiology, and end results database, 1990\u20132008","volume":"134","author":"Schlichting","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2024.115097_bib23","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10549-015-3436-x","article-title":"Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis","volume":"152","author":"Fouad","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2024.115097_bib24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13058-019-1201-5","article-title":"Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer","volume":"21","author":"van Uden","year":"2019","journal-title":"Breast Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924017040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924017040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T03:33:47Z","timestamp":1733974427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924017040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":24,"alternative-id":["S0959804924017040"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115097","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115097"}}